Yuhan Corporation
000100
Rank in Stocks
#3833
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in... Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
Share Price
$63.22
Market Cap
$4.27B
Change (1 day)
-3.12%
Change (1 year)
-23.57%
Country
KR
Trade Yuhan Corporation (000100)
Category
Healthcare
P/B ratio for Yuhan Corporation (000100)
P/B ratio as of October 2026 TTM: 3.01
According to Yuhan Corporation latest financial reports and stock price the company's current price-to-book ratio (TTM) is 3.01. At the end of 2024 the company had a P/B ratio of 4.26.
P/B ratio history for Yuhan Corporation from 2007 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 3.01 | -23.89% |
| 2025 | 3.95 | -7.28% |
| 2024 | 4.26 | 66.37% |
| 2023 | 2.56 | 24.28% |
| 2022 | 2.06 | -6.66% |
| 2021 | 2.21 | -17.25% |
| 2020 | 2.67 | 56.39% |
| 2019 | 1.71 | 23.87% |
| 2018 | 1.38 | -0.40% |
| 2017 | 1.38 | 6.44% |
| 2016 | 1.30 | -33.49% |
| 2015 | 1.96 | 49.31% |
| 2014 | 1.31 | -13.72% |
| 2013 | 1.52 | 4.85% |
| 2012 | 1.45 | 25.35% |
| 2011 | 1.15 | -32.24% |
| 2010 | 1.70 | -8.86% |
| 2009 | 1.87 | -22.38% |
| 2008 | 2.41 | -0.50% |
| 2007 | 2.42 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 1.9834 | -34.03% |
DE
|
|
| 2.1139 | -29.69% |
DE
|
|
| 1.3124 | -56.35% |
JP
|
|
| 6.3468 | 111.10% |
CH
|
|
| 5.0287 | 67.26% |
IN
|
